AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

AstraZeneca says lung ******* ***** trial shows no significant improvement in overall survival, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

London: Detailed results from one of AstraZeneca’s key lung ******* trials released on Monday showed that its experimental precision ***** did not significantly improve overall survival results for patients in the trial.

The overall survival, or OS rates, in the TROPION-Lung01 trial “did not reach statistical significance”, the company said in a presentation at the World Conference on Lung ******* in San Diego.

The late-stage trial has been closely watched by investors and by analysts who forecast that the *****, known as Dato-DXd, could potentially be another best-selling medicine for the company.

The trial compared the two treatments — AstraZeneca’s ***** and chemotherapy — of patients whose non-small cell lung ******* had returned after one or two prior treatment attempts.

Previous data releases related to the trial have knocked shares. In July 2023, the drugmaker’s shares fell by as much as 8 per cent after the company released interim data on progression-free survival, or PFS. And they fell again later in the year after the company released more PFS data related to the trial.

Overall survival is another important efficacy criterion for ******* drugs.

The *****, known as Dato-DXd, belongs to a promising class known as antibody ***** conjugates (ADC), which consist of tumour-seeking monoclonal antibodies that are combined with a cell-******** chemotherapy payload. It has been developed jointly with Japan’s Daiichi Sankyo.

(Reporting by Maggie Fick Editing by Christina Fincher)

• Published On Sep 10, 2024 at 06:21 AM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#AstraZeneca #lung #******* #***** #trial #shows #significant #improvement #survival #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up